Docon Technologies Private Limited has announced the partial redemption of its Series 1 Non-Convertible Debentures aggregating to INR 1,200 million. The redemption was achieved through a reduction in the face value per debenture from INR 10,00,000 to INR 9,00,000. This financial move, effective as of March 30, 2026, updates the outstanding principal and debenture holder details while leaving the company’s encumbered shareholding in Thyrocare Technologies Limited unchanged.
Details of Debt Repayment
On March 30, 2026, Docon Technologies Private Limited successfully completed a partial redemption of its Series 1 Non-Convertible Debentures. The total value redeemed amounts to INR 1,200 million. This transaction was executed by reducing the face value of each debenture by INR 1,00,000, bringing the new face value down to INR 9,00,000 per debenture.
Impact on Shareholding and Obligations
Following this financial adjustment, the total nominal value of the debentures now stands at INR 10,800 million. Importantly, the number of shares of Thyrocare Technologies Limited encumbered by Docon Technologies remains unchanged. These shares continue to be pledged with Catalyst Trusteeship Limited to secure the obligations of API Holdings Limited, which is the holding company for Docon Technologies.
Updated Investor Landscape
As part of this disclosure, the company has updated the list of debenture holders to reflect the current position. Key institutional investors involved in this debt facility include 360 One Prime Limited (INR 2,497.50 million), Micro Labs Limited (INR 2,266.20 million), and Tata Capital Limited (INR 1,125.00 million), among several other entities and high-net-worth participants.
Source: BSE
